News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,560 Results
Type
Article (13938)
Company Profile (299)
Press Release (247323)
Section
Business (79411)
Career Advice (151)
Deals (13199)
Drug Delivery (34)
Drug Development (50328)
Employer Resources (31)
FDA (5682)
Job Trends (5121)
News (144209)
Policy (10023)
Tag
Academia (902)
Alliances (21536)
Alzheimer's disease (750)
Approvals (5656)
Artificial intelligence (68)
Bankruptcy (97)
Best Places to Work (4524)
Biotechnology (245)
Breast cancer (107)
Cancer (856)
Cardiovascular disease (67)
Career advice (132)
CAR-T (68)
Cell therapy (208)
Clinical research (40063)
Collaboration (278)
Compensation (121)
COVID-19 (1005)
C-suite (76)
Cystic fibrosis (66)
Data (960)
Diabetes (81)
Diagnostics (1209)
Earnings (29000)
Events (47172)
Executive appointments (227)
FDA (6027)
Funding (292)
Gene editing (63)
Gene therapy (161)
GLP-1 (306)
Government (1064)
Healthcare (6546)
Infectious disease (1041)
Inflammatory bowel disease (98)
IPO (7197)
Job creations (859)
Job search strategy (127)
Layoffs (186)
Legal (1376)
Lung cancer (123)
Lymphoma (57)
Manufacturing (79)
Medical device (2563)
Medtech (2564)
Mergers & acquisitions (6123)
Metabolic disorders (243)
Neuroscience (987)
NextGen Class of 2024 (2002)
Non-profit (848)
Northern California (1053)
Obesity (134)
Opinion (91)
Parkinson's disease (70)
Patents (59)
People (25092)
Phase I (14118)
Phase II (18630)
Phase III (11802)
Pipeline (358)
Postmarket research (851)
Preclinical (5971)
Radiopharmaceuticals (205)
Rare diseases (196)
Real estate (1409)
Regulatory (8262)
Research institute (932)
Southern California (949)
Startups (1965)
United States (8405)
Vaccines (165)
Weight loss (78)
Date
Last 7 days (434)
Last 30 days (1528)
Last 365 days (20522)
2024 (20078)
2023 (22419)
2022 (26835)
2021 (27817)
2020 (23385)
2019 (16249)
2018 (11770)
2017 (13768)
2016 (11850)
2015 (14358)
2014 (10395)
2013 (7487)
2012 (7543)
2011 (7617)
2010 (7431)
Location
Africa (146)
Asia (16907)
Australia (2849)
California (2389)
Canada (783)
China (193)
Colorado (88)
Connecticut (99)
Europe (36413)
Florida (261)
Georgia (68)
Illinois (145)
Indiana (60)
Kansas (55)
Maryland (320)
Massachusetts (1898)
Michigan (54)
Minnesota (99)
New Jersey (609)
New York (666)
North Carolina (412)
Northern California (1053)
Ohio (81)
Pennsylvania (459)
South America (207)
Southern California (949)
Texas (267)
Washington State (243)
261,560 Results for "maverick therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Beyeonics Surgical Announces the First Use of the Beyeonics Maverick System in Surgery
The Beyeonics™ Maverick system has been used in surgery for the first time to successfully give surgeons enhanced visual and operational capabilities during neurosurgical and orthopedic procedures.
May 20, 2024
·
2 min read
Press Releases
Maverick Medical AI Announces Completion of The Implementation of Its Real-Time Autonomous Medical Coding Solution at RadNet
December 1, 2024
·
3 min read
Genetown
908 Devices Launches MAVERICK for Real-Time In-Line Monitoring of Multiple Bioprocess Parameters
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces the launch of MAVERICK.
September 18, 2023
·
6 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Drug Development
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
Allakos Inc. today announced topline data from its phase 2 clinical trial in patients with atopic dermatitis (ATLAS) and from its Phase 2b clinical trial in patients with chronic spontaneous urticaria (MAVERICK).
January 16, 2024
·
6 min read
Drug Development
Sorrento Announces FDA Authorization to Proceed With Phase 2 Study of Abivertinib (Fujovee™) to Treat Metastatic Castrate Resistant Prostate Cancer (MAVERICK Trial)
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that it has received clearance from the FDA for its investigational new drug application (IND) for Abivertinib (Fujovee™) for the Phase 2 MAVERICK study to be conducted in participants with metastatic castrate resistant prostate cancer (mCRPC) at multiple centers in the United States.
May 17, 2022
·
7 min read
Press Releases
Terray Therapeutics Closes Oversubscribed $120M Series B to Advance Its Generative AI Pipeline of Small Molecule Therapeutics to the Clinic
October 18, 2024
·
3 min read
Deals
Takeda to Acquire Maverick Therapeutics to Advance T-Cell Engager Therapies for Solid Tumors and Expand Novel Immuno-Oncology Portfolio
Acquisition expands Takeda’s immuno-oncology portfolio with two development candidates and Maverick’s conditionally active bispecific T-cell engagers COBRA™ platform, specifically designed to target solid tumors Maverick’s lead candidate TAK-186 (formerly MVC-101), a conditionally active T-cell engager, is first in its class to enter the clinic with recent Phase 1/2 study initiation
March 9, 2021
·
10 min read
Regulatory
FDA Warns Applied Therapeutics of ‘Objectionable Conditions’ in Govorestat Study
The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical trial—including a dosing error for govorestat—claims that the company said it had already addressed.
December 4, 2024
·
2 min read
·
Tristan Manalac
Press Releases
NeuroEM Therapeutics(R) Accepted into StartUp Health’s Alzheimer’s Moonshot Community(TM)
September 19, 2024
·
4 min read
1 of 26,156
Next